PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
about
Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials.Lipoprotein (a) and coronary heart disease - is there an efficient secondary prevention?PCSK9 targets important for lipid metabolismPathobiology of Lp(a) in calcific aortic valve disease.Evolocumab for the treatment of hypercholesterolemia.Alirocumab for the treatment of hypercholesterolemia.Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Lipoprotein(a): A missing culprit in the management of athero-thrombosis?Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up.Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapyRoles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling: Adding the Plasminogen Receptor PlgRKT to the List.The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab.Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease
P2860
Q36268257-70D47C7A-1F2F-4862-AF33-C8C9909101EAQ37703198-187CBE9B-1E4A-4078-84F5-F0A752B7C811Q37703261-FA9C9AD4-D232-4FF2-9ECF-D5AE7D6961B9Q38620736-BA51F8F6-7424-44F1-97DB-D220FFFB56A0Q38622565-ECC0C55B-4857-4CA1-A15C-97E7CD3833F0Q38917894-F33FE7E9-BAD9-48A1-96C7-FE3E25A08429Q38985774-3AF171D9-9F54-44AB-8876-B8EB8E3BAC78Q39030028-0FE4EDB9-9A53-4B5D-9EAA-D953FED72F73Q39368804-92A28A86-8EB3-420F-BC9C-BBD8372860DFQ39443793-0085B681-4899-4A81-B1A9-4236D6664AE7Q39458225-3D638B6C-E015-4BAA-B7E7-3E51FD27C5C0Q40984110-D17D15DC-1DF5-4FEB-824B-6FF4419F69DCQ41153491-ECCC2032-2A3D-4121-AA23-EE175598B48AQ41503652-A4DB86F0-2428-43CE-90A4-C0881BAF505AQ46066892-02B8AAF2-C31E-4917-B843-76A863DE93F5Q46857725-0B13F6DC-3A0E-422E-97F4-1277A6186C61Q47274864-6ECE5C04-4FC7-4C5C-BD76-9C47B4A1D57AQ48209248-B09A070F-F5C7-45A8-B83F-1B4D3D4999C6Q49898645-8B1B6A02-2048-4A73-B8EB-9E8B7687FE86Q50157113-073C99D5-AD0E-4223-8F5D-E77F5FBD718FQ58803104-F6183D30-FFAC-45C4-8248-4DE669F06D28
P2860
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PCSK9 inhibition-mediated redu ...... s and the LDL receptor's role.
@en
type
label
PCSK9 inhibition-mediated redu ...... s and the LDL receptor's role.
@en
prefLabel
PCSK9 inhibition-mediated redu ...... s and the LDL receptor's role.
@en
P2093
P2860
P356
P1476
PCSK9 inhibition-mediated redu ...... s and the LDL receptor's role.
@en
P2093
Armando Lira
Evan A Stein
Frederick J Raal
Marc S Sabatine
Matthew Peach
Michael J Koren
Narimon Honarpour
P2860
P304
P356
10.1194/JLR.P065334
P577
2016-04-21T00:00:00Z